Bioadhesive Matrix Tablets Loaded with Lipophilic Nanoparticles as Vehicles for Drugs for Periodontitis Treatment: Development and Characterization by Murgia, Denise et al.
polymers
Article
Bioadhesive Matrix Tablets Loaded with Lipophilic
Nanoparticles as Vehicles for Drugs for Periodontitis
Treatment: Development and Characterization
Denise Murgia 1,2 , Giuseppe Angellotti 2, Fabio D’Agostino 3 and Viviana De Caro 2,*
1 Dipartimento di Discipline Chirurgiche, Oncologiche e Stomatologiche, Università degli Studi di Palermo,
90127 Palermo, Italy; denise.murgia@unipa.it
2 Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli
Studi di Palermo, 90123 Palermo, Italy; angellotti.gius@gmail.com
3 Istituto per lo Studio degli Impatti Antropici e Sostenibilità dell’Ambiente Marino, Consiglio Nazionale delle
Ricerche (IAS – CNR), Campobello di Mazara, 91021 Trapani, Italy; fabio.dagostino@cnr.it
* Correspondence: viviana.decaro@unipa.it; Tel.: +39-091-2389-1926
Received: 16 October 2019; Accepted: 30 October 2019; Published: 2 November 2019


Abstract: Periodontitis treatment is usually focused on the reduction or eradication of
periodontal pathogens using antibiotics against anaerobic bacteria, such as metronidazole (MTR).
Moreover, recently the correlation between periodontal diseases and overexpression of reactive
oxygen species (ROS) led to the introduction of antioxidant biomolecules in therapy. In this work,
bioadhesive buccal tablets, consisting of a hydrophilic matrix loaded with metronidazole and lipophilic
nanoparticles as a vehicle of curcumin, were developed. Curcumin (CUR)-loaded nanostructured
lipid carriers (NLC) were prepared using glycyrrhetic acid, hexadecanol, isopropyl palmitate and
Tween®80 as a surfactant. As method, homogenization followed by high-frequency sonication was
used. After dialysis, CUR-NLC dispersion was evaluated in terms of drug loading (DL, 2.2% w/w)
and drug recovery (DR, 88% w/w). NLC, characterized by dynamic light scattering and scanning
electron microscopy (SEM), exhibited a spherical shape, an average particle size of 121.6 nm and PDI
and PZ values considered optimal for a colloidal nanoparticle dispersion indicating good stability of
the system. Subsequently, a hydrophilic sponge was obtained by lyophilization of a gel based on
trehalose, Natrosol and PVP-K90, loaded with CUR-NLC and MTR. By compression of the sponge,
matrix tablets were obtained and characterized in term of porosity, swelling index, mucoadhesion
and drugs release. The ability of the matrix tablets to release CUR and MTR when applied on buccal
mucosa and the aptitude of actives to penetrate and/or permeate the tissue were evaluated. The data
demonstrate the ability of NLC to promote the penetration of CUR into the lipophilic domains of the
mucosal membrane, while MTR can penetrate and permeate the mucosal tissue, where it can perform
a loco-regional antibacterial activity. These results strongly support the possibility of using this novel
matrix tablet for delivering MTR together with CUR for topical treatment of periodontal diseases.
Keywords: buccal matrix tablets; nanostructured lipid carriers; NLC; metronidazole; curcumin; oral
mucosal drug delivery; buccal delivery; hydrophilic sponge; periodontitis; oral disease
1. Introduction
Bacterial infections are among the most common diseases that could affect the oral mucosae.
An immunocompromised state of the oral cavity is related to systemic and local factors that could
allow the development of infections. Moreover, antibiotic multi-resistance is becoming frequent in
bacterial pathogens and it may cause the overgrowth of microorganisms [1].
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In particular, periodontal disease is a bacterial infection associated with the overgrowth of
anaerobic organisms and, in certain instances with the micro-aerophilic ones, resulting in chronic
inflammation of the gingiva [2]. Their action results in progressive connective tissue loss enhanced by
the host’s inflammatory factors, which can lead to tooth loss [3].
In addition to bacterial action, frequently oral lesions are exasperated by the presence of
reactive oxygen species (ROS). Their overproduction that is not balanced by an adequate level
of antioxidants can prompt oxidative stress damages. In periodontal disease, most of the damage is
induced by inflammatory mediators, involving free radical increasing from the neutrophil/macrophage
anti-bacterial response [4]. For this reason, the administration of antioxidant substances in periodontal
diseases has recently been extensively studied [5].
Periodontitis treatment is usually focused on the reduction or eradication of periodontal pathogens
using antibiotic agents [6].
Metronidazole (MTR) is the first-line antimicrobial agent in the treatment of inflamed periodontal
pockets [7], attributable to its activity spectrum against both Gram-negative and Gram-positive
anaerobic bacteria and its limited side effects [6,8]. Nonetheless, a prolonged systemic administration
of MTR in periodontal disease can raise several issues, such as the increased risk of antibiotic resistance
and the presence of side effects like nausea, diarrhea and pseudomembranous colitis [9].
Since oxidative stress is involved as an etiological component of these diseases, a treatment
involving MTR together with antioxidant agents could be suitable to obtain synergic action.
Curcumin (CUR) is a natural polyphenolic compound obtained from the rhizome of
Curcuma longa, where it is present with other characteristic compounds (demethoxycurcumin and
bisdemethoxycurcumin) known as curcuminoids [10]. It has been studied for its several pharmaceutical
properties, such as being antibacterial [11], antioxidant, anti-inflammatory [12], anti-cancer and a
wound healing agent [13].
This compound was frequently used in the treatment of oral lesions, periodontitis in particular,
because of its several mechanisms and molecular targets mediating the anti-inflammatory action.
It suppresses the activation of the transcription factor NF-κB, cytokines such as TNF-α, IL-1, -2, -6, -8,
-12, mitogen-activated protein kinase (MAPK) and c-Jun N terminal kinase (JNK), and downregulates
the expression of cyclo-oxygenase-2 (COX-2), lipoxygenase (LOX) and the inducible nitric oxide
synthase (iNOS) [14]. Evidences from both in vitro and in vivo studies show that CUR is able to
decrease the response of immune cells to periodontal disease-associated bacterial antigens, inhibiting
periodontal tissue destruction [15].
CUR is chemically unstable, practically insoluble in water and soluble in solvents such as ethanol
and acetone. In the gastrointestinal environment, it suffers slow solubilization and fast degradation
that limit absorption. Moreover, a short plasma half-life drastically reduces its action in vivo [16].
Considering the limits of both MTR and CUR systemic administration and the site-specific
condition of destructive periodontal disease, a local administration could be an improved treatment
for several oral pathologies, since there are minor risks of systemic side effects [17].
Conventional dosage forms may not be accurate due to fast dissolution and disintegration during
the application period, while drug delivery systems (DDS) expressly designed to deliver substances in
oral mucosa are preferred to promote high concentrations of actives directly into periodontal pockets,
improving the in loco treatments. They are designed to stay in contact with the mucosa longer, provide
more accurate drug dosing and covering a larger surface area, suited to protect oral wound surfaces [18].
Furthermore, due to its relative immobility, buccal mucosa is a desirable region for retentive systems
used for transmucosal drug delivery.
Mucoadhesion is a critical parameter for buccal administration, so materials with optimal adhesive
properties, such as mucoadhesive polymers, should be selected. These polymers play an important
role in designing bioadhesive oral formulations, since their ability to create strong adhesive contacts
with tissues increases the residence time in the target site of such systems [19].
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Recently, new mucoadhesive systems, suitable to treat buccal affections, were developed.
Buccal tablets are one of the most commonly investigated dosage forms for buccal administration,
especially the mucoadhesive ones that give less discomfort in drinking and speaking than the
conventional tablet. They can promote drug absorption rates by slow dissolution and erosion [20].
Moreover, molecular size affects the permeability of macromolecules through the oral mucosa, so the
drug incorporation as part of nanostructured delivery systems could be developed to enhance the
penetration on the target site. Thus, bioadhesive nanoparticles could be more advantageous due to
their ability to create intimate contact with larger mucosal surface areas [21].
Nanostructure lipid carriers (NLC) represent a new generation of nanoparticles together with
solid lipid nanoparticles (SLN). They are colloidal carrier systems able to deliver active substances,
and protect them against chemical degradation, and are mainly used for a controlled release in topical
administration [22].
The aim of this work is the formulation, development and characterization of buccal tablets
obtained from hydrophilic sponges made by NLC with curcumin (CUR-NLC) entrapped in a dry
hydrophilic matrix loaded with MTR. The obtained DDS consists of a bifunctional system able to
release CUR and MTR once on the application site, being suitable for the local treatment of several
oral diseases.
2. Materials and Methods
2.1. Materials
Curcumin (CUR) was purchased from Alfa Aesar (Haverhill, MA, USA), 1-Hexadecanol (HEXA) from
Farmalabor (Canosa di Puglia, Italy) isopropyl palmitate (IP), glycyrrhetic acid (GA) and metronidazole
(MTR) from A.C.E.F S.p.a. (Fiorenzuola d’Arda, Italy), Tween 20 and Polyvinylpyrrolidone (PVP-K90)
from Sigma-Aldrich (Milan, Italy), Hydroxyethylcellulose (Natrosol™ 250) from Galeno (Comeana PO,
Italy) and trehalose dihydrate from la Hayashibara Shoji Inc (Okayama, Japan).
Non-enzymatic artificial plasma of pH 7.4 (PBS) was prepared dissolving 2.80 g of KH2PO4 and
20.5 g of Na2HPO4 in1 L of distilled water and the same conditions were used for the non-enzymatic
artificial plasma of pH 7.4 (PBS) with 5% and 10% of DMSO.
A buffer pH 6.8 solution simulating salivary fluid was prepared using KCl (1.5 g), NaHCO3
(1.75 g), (KSCN 0.5 g), Na2HPO4 H2O (0.5 g) and lactic acid (1 g) in distilled water; 0.9% saline solution
was prepared by dissolving 9 g of NaCl in 11 L of distilled water.
Citrate buffer 10 mM (pH 6.2) used for NLC preparation was obtained dissolving 2.675 g of
sodium citrate dehydrate and 0.190 g of citric acid monohydrate in 1 L of distilled water.
All chemicals and solvents of analytical grade were purchased from VWR International (Milan,
Italy) and used without further purification. Porcine mucosae were kindly supplied by the Municipal
Slaughterhouse of Villabate (Palermo, Italy).
For data processing, we used Kaleidagraph v. 3.5 (Synergy Software Inc, Reading, PA, USA) and
Curve Expert 1.34 for Windows as software.
2.2. Lipid Ratio Mixtures Screening Studies
Lipid mixtures (LM) prepared changing both the ratio of the components and CUR are reported
in Table n.1.
A calculated amount (1 g) of each LM was melted and stirred using a silicon bath placed on a hot
plate (Heidolph MR2001 K equipped with EKT 3001 electronic temperature control, Germany), until
the mixture appeared clear and CUR was completely solubilized, then cooled at room temperature
and finally stored at 2–4 ◦C. After 24 h, the melting point of the mixtures was evaluated using Büchi
Melting Point B-540 instrument sets at increasing temperature speed of 5 ◦C/min. The analysis was
carried out in triplicate and the result was expressed as the mean of the values obtained.
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2.3. Preparation of CUR-Loaded NLC
Aliquots of 100 mg of each lipid mixture were added to 20 mL of 10 mM citrate buffer of pH
6.2 with 0.5% or 1% (w/v) of Tween 20 as a surfactant and homogenized (Polytron Model PT MR
2100 Homogenizer, Kinematica, Luzern, Switzerland) for 1 min. Then a high-frequency sonication
treatment using a SONOPULS instrument (mod. HD 2070, Bandelin, Berlin, Germany) at a pulsating
frequency of 20 kHz with 0.7 s of activity (on) and 0.3 s of inactivity (off) was performed. Samples were
treated with two cycles of sonication (10 min each), the first one at room temperature and the second at
0 ◦C by immersing the container in an ice/water/NaCl bath.
2.4. NLCs Characterization
2.4.1. Dynamic Light Scattering (DLS) and Z-Potential Measurements
The mean particle size (Z-average), the polydispersity index (PDI) measuring the distribution of
the nanoparticle population and the electrical charge on the surface of the nanoparticles (zeta potential,
ZP) were determined using a Nano-ZS Zetasizer (Malvern Instruments, Malvern, UK). DLS measures
the fluctuations in scattered light intensity due to diffusing particles and represents one of the most
powerful techniques to assess particle size [23]. To avoid multiple scatterings of the light caused by a
high concentration of particles, samples were prepared by diluting 1 mL of fresh NLC dispersion in
9 mL distilled water. All analyses were performed at 25 ◦C, under an electrical field of 40 V for ZP
analyses, carrying them out in duplicates. Empty NLCs (without CUR) were analyzed to evaluate a
potential CUR influence on mean particle size, distribution and stability.
2.4.2. Morphology by Scanning Electron Microscopy (SEM)
SEM analyses were performed to evaluate the morphology and topographic characteristics of
both loaded nanoparticles and sponges loaded with MTR and CUR-NLC.
Measurements were carried out using a Zeiss EVO MA10 (Carl Zeiss Microscopy GmbH, Jena,
Germany) scanning electron microscope, equipped with a SE-Everhart-Thornley secondary electron
detector having as source of electrons a Lanthanum Hexaboride (LaB6) cathode. The accelerating
voltage and probe voltage were, respectively, 20 keV and 10 pA.
The scanning electron microphotographs were acquired in ultra-vacuum condition (HV, about
10−7 mbar) and magnified up to 50.000× (200 nm).
To analyze CUR-NLCs, a few drops of fresh CUR-NLC dispersion put on an aluminium stub were
placed in a CaCl2 desiccator at 8 ◦C for 24 h and then coated with an ultrathin layer of gold (thickness
about 2 nm) with an AGAR Sputter Coater type system, to increase the surface electrical conductivity.
The gold coating was also made for the samples of sponge loaded with MTR and CUR-NLC before
each analysis.
2.4.3. Entrapment Efficacy, Drug Loading and Drug Recovery of NLCs
The entrapment efficiency (EE), loading capacity (LC) and Drug Recovery (DR) were indirectly
determined, calculating the amount of free CUR in the aqueous phase, applying Equations (1)–(3),
respectively [24]:
EE%
(w
w
)
=
CUR in formulation− free CUR
CUR in formulation
× 100, (1)
DL%
(w
w
)
=
CUR in formulation− free CUR
Lipids amount
× 100, (2)
DR%
(w
w
)
=
CUR in formulation
CUR used
× 100. (3)
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CUR Quantification in Fresh NLC Dispersion
At the end of the NLCs preparation process the volume of the whole formulation was measured.
A total of 200 µL of NLC dispersion was withdrawn, transferred into a 10 mL flask and brought to
volume with methanol to solubilize all components. Samples were analyzed by HPLC to quantify the
total CUR (free and encapsulated) and detect any degradation products [25].
The free CUR, non-entrapped in nanoparticles, was investigated by two methods:
• Dialysis assay: Dialysis tube (molecular weight cut off, MWCO, 12–14,000 Da, Visking Dialysis
Membrane, Medicell Membranes Ltd., London, UK) was pre-activated and filled by 2 mL of
CUR-NLC dispersion and submerged in 350 mL of distilled water, keeping at room temperature
and under magnetic stir. After 24 h both the dispersion inside the tube and the external water
were analyzed by HPLC.
• Ultrafiltration assay: Aliquots of 0.45 mL of fresh samples were centrifuged (Microfuge 22R,
Beckman coulter™ Brea, CA, USA) in two Ultrafree-MC (Millipore, Burlington, MA, USA) devices,
with membrane cut-off of 10,000 NMWL and 30,000 NMWL, at 8000 rpm and 4 ◦C for 30 min [26].
In the end, the liquid ultrafiltrate was analyzed by HPLC.
2.5. Preparation of Sponges Loaded with MTR and CUR-NLC.
Firstly, a gel made by trehalose (30%), PVP K90 (0.8%) and Natrosol (5%) was prepared by adding
the components to distilled water at 60 ◦C and keeping in an ultrasonic bath until it appeared dense,
clear and completely homogeneous. Afterwards, it was stored at 4 ◦C for 24 h before use.
Sponges were prepared by adding in two different moments, 100 mg MTR and 4 g of gel to 20 mL
of CUR-NLC dispersion. After both the addictions, the sample was gently mixed and then treated
with a high-frequency sonication (20 kHz) with cycles of 0.7 s (on) and 0.3 s (off) for 2 min, keeping an
ice/water/NaCl bath around it. At the end the sample was stored at −80 ◦C for a night and then moved
in a freeze-dryer (Labconco FreeZone® 2.5 Liter Freeze Dry System) with a 0.014 mPa vacuum for 24 h.
The amount of MTR and CUR loaded in the sponges were determined analyzing three samples of
each lyophilized preparation in methanol, by UV-Vis spectrophotometry. Therefore, the morphology
of the obtained matrix was evaluated by SEM analysis.
Tablets Preparation
Two steel tablet moulds (PerkinElmer IR Accessory, Waltham, MA, USA) were used to have tablets
with different dimensions and weight. Sponges of 20 mg (to obtain Tablet A) and 200 mg (to obtain
Tablet B) were placed in molds with a d = 0.47 cm or d = 1.3 cm, respectively. Both were compressed
by a 300 g weight for about 30 min. The results are reported as average ± SE (n = 20).
2.6. Tablets Characterization
2.6.1. Porosity
Using freeze-drying the solvent is removed, and the space originally occupied by the solvent is
retained for the porous structure. The tablet porosity was calculated mathematically, as total pore
volume, using the following equation [27]:
%Porosity =
pratical volume− theoritical volume
pratical volume
× 100.
The bulk volume of the total ingredients of one sponge was calculated according to the equation:
Theoritical volume =
∑ mn
ρn
where m and % are the mass and density of each ingredient, respectively.
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The true volume of tablets was obtained calculating their dimensions as cylinders:
Practical volume = pir2 × h.
The results of these measurements were also supported by the SEM scanning electron micrographs.
2.6.2. Swelling Test
Swelling tests were performed on B tablets with both weight and optic assessments. For weight tests,
tablets were placed on microscope slides and weighted by an analytic balance (Mod. AE 240, Mettler-Toledo
S.p.A., Milan, Italy). Every 5 min for 20 min, 0.5 mL of artificial saliva (pH 6.8) were added on the tables
and after the removal of the excess water with a filter paper, the weight was assessed. The water uptake
was quantified gravimetrically until the weight-plateau or the cleavage of the tablets. Tests were performed
on six different tablets and results were reported as means ± SE (n = 9; p < 0.05).
Swelling Index =
W0 + (Wt −W0)
W0
× 100,
where Wt is the weight of film at time t, and W0 is the weight of dry film.
Both plan and frontal optical assessments were performed. Samples placed on glass were
positioned on graph paper and wet every 5 min for 2 h by 0.5 mL of simulated saliva (pH 6.8, 37 ◦C).
Each time interval a photograph was taken to evaluate any change in the tablet’s morphology.
2.6.3. Ex Vivo Mucoadhesion Strength Measurement
The ex-vivo mucoadhesion strength tests were performed on Tablet B using the modified two
armed physical balance method [28]. As model tissue, porcine buccal mucosa excised from slaughtered
pigs was used without any pre-treatment. A cyanoacrylate resin (Super Attak Loctite®, Henkel Italia
Srl, Milan, Italy) was used to glue a piece of mucosa on a glass support kept in a vessel placed in
a thermostatic bath at 37 ± 1 ◦C. This temperature was maintained during the whole experiment.
Before starting the measurements, the mucosa was wetted with 50 µL of simulated salivary fluid.
The tablet was fixed using double-sided tape to the lower side of a rubber stopper hanging from the
balance arm and then placed just touch the wet mucosal surface; a light force with a fingertip was
applied for 20 s.
The measures started 5, 10, 15 and 20 min after tablet placement. The grams required to detach it
from the mucosal surface provided the measurement of mucoadhesive strength.
The force of adhesion and the detachment force were calculated using the following equations,
respectively [28], and each experiment was performed in triplicate:
Force o f adhesion (N) = g × 9.81/1000,
Detachment f orce
(
N/m2
)
= Force o f adhesion (N)/sur f ace area
(
m2
)
.
2.6.4. In Vitro CUR and MTR Release Studies
The in vitro CUR and MTR release from tablets was carried out using a Franz diffusion
cell (Permeagear, flat flange joint, 9 mm orifice diameter, 15 mL acceptor volume, SES
GmbH-Analysesysteme, Bechenheim, Germany). A Cellulose nitrate membrane with a 0.45 µm
pore size (Millipore) was soaked with acceptor fluid and fixed between the donor and receptor
compartment [29].
The receiver chamber was filled with phosphate buffered to pH 6.2 plus Tween 20 (8% w/v) as a
surfactant to increase the solubility and stability of MTR and CUR in the receiver media [30].
The temperature of receptor media was kept at 37 ± 0.5 ◦C. The donor chamber was filled with
Tablet A (20 mg, area = 0.2 cm2) containing MTR and CUR-NLC and 0.5mL of simulated saliva.
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At regular time intervals (15 min), samples (0.5 mL) were withdrawn from the acceptor compartment
and the sample volume was taken out and replaced with fresh fluid. The samples were analysed
by UV-Vis using the appropriate blank and calibration curve. The permeation experiments were
carried out for 3 h and results were reported as means ± SE (n = 6). Release data were elaborated
using Kaleidagraph v. 3.5 software and fitted to the semi-empirical equation that is usually applied to
describe drug release from polymeric systems [31]. Linear or non-linear least squares fitting methods
were used to determine the optimum values for the parameters present in each equation. Fittings were
validated by using χ2. A p-value of less than 0.05 was considered to be statistically significant.
2.7. Ex Vivo Permeation and Penetration of CUR and MTR throughout Porcine Buccal Mucosa
The permeation or/and penetration of CUR and MTR released from tablets through the porcine
buccal mucosa, was evaluated using Franz type diffusion cells (Permeagear, flat flange joint, 9 mm
orifice diameter, 15 mL acceptor volume, SES GmbH-Analysesysteme, Bechenheim, Germany), used as
a two-compartment open model. Mucosal specimens (kindly supplying by Municipal Slaughterhouse
of Villabate, Palermo, Italy) consisted of tissue removed from the vestibular area of the retromolar
trigone (buccal mucosa) of freshly slaughtered domestic 6–8-month-old pigs were used as a membrane.
They were prepared as described previously [32].
The specimens, transferred in the laboratory within 2 h from animal sacrifices, were surgically
treated to remove the excess of adipose and connective tissues and then stored at –20 ◦C for periods
up to one week. Before the experiments they were equilibrated at room temperature and dipped for
about 1 min in saline solution at 60 ◦C; the connective tissue was carefully peeled off from the mucosa
(slides 250 ± 25 µm and 100 ± 25 µm thick for buccal and sublingual tissues, respectively) to obtain the
heat-separated epithelium along with the intact basal lamina [33].
The thickness was measured using a digital micrometer. After this heath treatment, which is able
to not modify the permeability and/or integrity of the mucosae [32], specimens were equilibrated in
PBS for about 3 h at room temperature to remove biological matter that could interfere with analysis.
The equilibration medium was replaced with fresh PBS every 15 min.
The Franz diffusion cells were equilibrated for 30 min at 37 ± 0.5 ◦C, mounted with buccal mucosa
as membrane, PBS (pH 7.4) with 10% DMSO as acceptor compartment and 1 mL and simulated saliva
in donor chamber. This step was followed by the removal of donor compartment solution, immediately
replaced with a Tablet A (area = 0.2 cm2) containing MTR and CUR-NLC and 0.4mL of simulated saliva.
At regular time intervals (30 min), samples (0.5 mL) were withdrawn from the acceptor compartment
and the sample volume was taken out and replaced with fresh fluid. The permeation experiments were
carried out for 4 h. The CUR and MTR amount in acceptor chamber were quantitatively determined
by UV-Vis spectrophotometry using the appropriate blank and calibration curve and results were
reported as means ± SE (n = 12).
At the end of each experiment, mucosal integrity was checked as previously described [34].The
flux values (Js) across the membranes were calculated at the steady state per unit area by linear
regression analysis of permeation data, following the relationship Js = Q/At (mg/cm2·h), where Q is the
amount of drugs recovered in the acceptor compartment, A is the cross-sectional area available for
diffusion (0.636 cm2), and t is the time of exposure (h). Data were elaborated using Kaleidagraph 3.5
(Sinergy Software Inc., Reading, PA, USA) as software.
Quantification of CUR and MTR Entrapped into Porcine Mucosa
At the end of each experiment, the residual MTR and CUR amount entrapped into the mucosal
tissue were quantified by extraction. Each mucosa specimen was washed with PBS (3 × 2 mL) and
was then dipped for 5 min in warmed (50 ◦C) methanol (1.5 mL). The extraction was repeated three
times and the collected mother liquors were quantitatively transferred in a 5 mL flask and brought to
volume. The amount of drugs extracted was evaluated by UV and HPLC analysis using the appropriate
calibration curve and blank. The same extraction treatment was also performed on mucosal specimens
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subjected to an experimental phase in the absence of drugs and was used as the control. Data were
reported as percentage amount of CUR and MTR into the tissue. Moreover, the Accumulation (Ac)
parameter was calculated using the following equation:
Ac (cm) = [Q (mg)/A (cm2)]/Cd (mg/cm3)
where Q is the amount of drug which remains entrapped into the buccal tissue at the end of permeation
experiments, A is the active cross-sectional area available for diffusion (0.636 cm2), and Cd is drug
concentration in the donor compartment (mg/cm3) [35].
2.8. Drugs Assay
2.8.1. UV-Vis Method
The amount of drugs loaded in NLCs and sponges, as well as drugs detected during release and
permeation experiments, were measured spectrophotometrically using the appropriate calibration
curves and blanks (UV/VIS mod. Pharma Spec 1700, Shimadzu, Tokyo, Japan) with simple, accurate
and reproducible methods.
For CUR determination, for λmax = 428 nm, two calibration curve in methanol were performed: In
the linearity range of 0.0002–0.0075 mg/mL, the regression equation was Abs = −0.0289 + 132x (mg/mL)
(R = 0.999, SE 0.0101) and in the linearity range of 0.0025–0.01 mg/mL, the regression equation was Abs
= −0.0108 + 136 x (mg/mL) (R = 0.997, SE 0.0397).
The calibration curve in the phosphate buffer of pH 6.2 plus Tween 20 (8% w/v) was in the
linearity range of 0.0001–0.001 mg/mL, and the regression equation was Abs = 0.01277 + 160x (mg/mL)
(R = 0.997, SE 0.0105).
For MTR determination were found validation parameters in methanol, in PBS and in phosphate
buffer (pH 6.2) plus Tween 20 (8% w/v), at λmax = 310 nm. For methanol, the linearity range was
0.0025–0.03 mg/mL, and the regression equation Abs = 0.0011+ 62x (mg/mL) (R = 0.999, SE 0.0092);
for PBS the linearity range was 0.0025–0.0125 mg/mL, and the regression equation Abs = 0.0011 +
61.78x (mg/mL) (R = 0.999, SE 0.0040). For the phosphate buffer (pH 6.2) plus Tween 20 (8% w/v),
the linearity range was 0.0025–0.02 mg/mL, and the regression equation was Abs = 0.0771 + 46.8x
(mg/mL) (R = 0.998, SE 0.0102).
At the testing concentrations, no interferences between drugs and components of formulations
were observed and no change in drug absorbance at its λmax was experienced in the presence of
excipients. In analogy, the amount of drugs founded in acceptor and/or entrapped into the membrane
were measured after withdrawal or extraction from mucosal tissue by methanol. Intraday and interday
variations, observed during the collection of experimental data, were lower than sensibility.
2.8.2. HPLC Method
HPLC analyses were performed with an HPLC Shimadzu LC-10AD VP instrument (Tokyo,
Japan) equipped with a binary pump LC-10AD VP, a UV SPD-M20A Diode Array detector, a 20 µL
injector and a computer integrating apparatus (EZ Start 7.4 software, Shimadzu Scientific Instruments,
Inc., Columbia, MD, USA). Chromatographic separation was achieved on a reversed-phase column
ACE® EXCEL 5 C18-AMIDE (5 µm, 4.6 mm × 125 mm), a mobile phase consisted of methanol (A)
acetate buffer 5 mM pH 6.5 (B). For separation the gradient method was developed as follows: A: B
(0.5:99.5→0.01–3.00 min, 80:20→3.00–7.00 min; 80:20→7.00–22.00 min; 0.5:99.5→22–26 min). The flow
rate was set at 1 mL/min, the UV wavelength range 200–700 nm and set 428, 310 and 250 nm to
identification of MTR, CUR and GA, respectively. In these conditions the retention time of MTR, CUR
and GA were 1.95, 12.42 and 15.68 min, respectively.
For CUR quantification, the calibration curve was performed in the concentration range of
0.0075–0.01 mg/mL. HPLC reports were highly reproducible and linearly related to concentration (R = 0.999).
Polymers 2019, 11, 1801 9 of 19
2.9. Data Analysis
Data were expressed as mean ± SE. For the statistical analysis of the data, Student’s t-test has
been applied with the minimum levels of significance with p < 0.05.
3. Results and Discussion
3.1. CUR-NLC Formulation and Characterization
In the pharmaceutical field, nano-encapsulation is highly exploited to promote the administration
of substances with a low ability to cross biological membranes, using natural and/or synthetic materials
to have a formulation with suitable chemical–physical characteristics. The low stability and solubility
in a water solution of curcumin involve its delivery by NLCs [25].
Therefore, as components for lipid mixtures were chosen, long-chain fatty alcohol, such as
1-Hexadecanol, isopropyl palmitate, a liquid excipient able to solubilize lipophilic drugs, and 18-β
glycyrrhetic acid (GA) with emulsifying properties. GA is a triterpenoid metabolite of glycyrrhizin,
extracted from the dried roots and rhizomes of Glycyrrhiza glabra [36], studied for its anti-ulcer,
antihepatotoxic, anti-microbial, anti-fungal, antitussive, anti-diabetic, anti-diuretic, skin whitening,
cytoprotective and cytotoxic activities [37]. Moreover, it is well known as antioxidant tested against
b-carotene destruction and LDL oxidation [38] and as anti-inflammatory agent, used for treating acute
and chronic dermatitis reducing skin lesion sizes [39].
In order to prepare CUR-NLCs with high loading capacity and good stability is crucial the choose
of a lipid mixture able to permit CUR solubilization and to confer to the whole mixture (lipids and CUR)
a melting point similar to the physiological temperature of the oral cavity. Indeed, once applied on the
mucosal target sites, NLC should undergo partitioning into the tissue and promote drug penetration.
Lipid screening study results (Table 1) showed how the ratios of high-melting and low-melting
components affect the final melting point of the mixes.
Table 1. Lipid mixture compositions.
Sample CUR % GA % HEXA % IP % Melting Point ◦C
Mixture 1 1 1 39.2 58.8 31 ± 2 ◦C
Mixture 2 1 1 58.8 39.2 40 ± 2 ◦C
Mixture 3 1 3 58 38 45 ± 2 ◦C
Mixture 4 2.5 3 56.7 37.8 48 ± 2 ◦C
Empty 0 3 57.3 38.2 42 ± 2 ◦C
Mixtures 1 and 2 had to be discarded for the low melting point, due to the high amount of IP,
while Mixtures 3 and 4 presented melting points suitable for NLCs preparation.
In particular, CUR up to 2.5% w/w showed completely solubilized in Mixture 4, which appeared
clear in the molten state.
Regarding the NLC preparation method, a homogenization followed by high-frequency sonication
was performed. A hot pre-emulsion of melted lipid mixture and the aqueous emulsifier phase is
obtained by hot homogenization, carried out at temperatures above the melting point of the lipids.
A citrate buffer at pH 6.2 was chosen as an aqueous medium due to the pH-dependent instability of
CUR showed as decomposition at a neutral or basic pH [40]. To reduce the particle size, sonication by
a high-intensity ultrasonic probe was performed at the same temperature. Subsequently, the obtained
hot nano-emulsion was treated by the second cycle of ultrasonication at 0 ◦C, which leads to the
crystallization of the lipids and NLC formation. All the obtained dispersions appeared stable,
homogeneous and easily to re-disperse.
Particle size, size distribution and Zeta potential are essential factors to value the stability of
colloidal systems, showing significant effects on the final nanoparticles’ behavior [41].
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Table 2 shows the DLS measurements of average particle size, particle size distribution and
electrical charge surface of the nanoparticles expressed respectively as Z-average, PDI and Z-potential.
Table 2. Results of dynamic light scattering (DLS) and Z-Potential measurements.
. Tween 20% Z-Average (nm) PDI Z-Potential (mV)
Mixture 3
0.5 100 0.242 −24.6
1 100 0.274 −24.4
Mixture 4
0.5 121.6 0.235 −37.4
1 121.8 0.272 −33.2
Empty 0.5 129.4 0.216 −8.4
The surfactant amount is an important factor to determine the nanoparticle physicochemical
characteristics due to its surface-active properties. To prepare NLCs with a smaller particle size,
the concentration of surfactant could be increased in order to decrease the interfacial tension between
lipid and aqueous phases. From Mixtures 3 and 4 were prepared CUR-NLCs with 0.5% or 1% of Tween
20, to evaluate any difference whether in particle size or system stability. The values were comparable
and they clearly suggested that the lowest percentage of surfactant was sufficient to cover the
surface of nanoparticles and prevent the lipid agglomeration during the homogenization process [42].
In particular, this stability may be enhanced by both the electrostatic repulsion between particles
with the same charge and the stabilization and steric hindrance of Tween 20 chains. Although NLC
containing 1% CUR showed smaller particle size and a good PDI value, the NLC from Mixture 4,
showing suitable average particle size, the PDI value that indicates a narrow size distribution and
Z-potential that reflects great physical stability of the dispersion, was preferred due to the higher CUR
load. These results demonstrate that the amount of CUR loaded into the NLC plays a fundamental
role in particle size.
The empty samples were also analyzed to understand the CUR contribution in system stability.
The lack of CUR caused an increase in the ZP value, while the other parameters did not change
significantly. However, this value suggests a low physical stability.
According to the last considerations, the formulations made by Mixture 4 and 0.5% Tween 20 were
chosen for the next characterizations.
To obtain information concerning the surface characteristics and the morphology of CUR-NLC,
SEM analysis was also performed and scanning electron micrographs are presented in Figure 1.
NLCs show uniform spherical shapes with smooth surfaces, and their sizes was found evenly within
the nanometer range. It is observable that the agglomeration of particles may be due to the lipid nature
of carriers and the sample treatment prior the SEM analysis.
The drug recovery (DR) of CUR was calculated from the effective volume of fresh NLCs dispersion
obtained (about 18 mL) with respect to the volume of buffer initially used (20 mL), where CUR resulted
in 0.11 mg/mL, determining the 88% of DR. Furthermore, no degradation products were detected
during CUR quantification by HPLC analyses.
EE and DL were indirectly determined, evaluating the amount of free CUR remaining left outside
the nanoparticles by the dialysis and the ultrafiltration assays. In both the analyses no free CUR was
found, so the EE was 100%. The DL calculated was of 2.2% (initial CUR 2.5%) that may be due to the
loss of volume of the sample during the preparation process.
However, the high EE and DL values confirm the solubility of CUR in the chosen lipids as well as
the suitable formulation design for CUR encapsulation.
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3.2. Sponges Loaded with MTR and CUR-NLCs and Tablet Formulation and Characterization
Sponges were prepared entrapping the CUR-NLCs and MTR in a mucoadhesive hydrophilic
polymeric matrix subsequently dried.
NatrosolTM, a nonionic, biocompatible, mucoadhesive, nontoxic polymer was chosen to prepare
a hydrogel together with PVP-90 as mucoadhesive plasticizer and trehalose as cryoprotectant.
These excipients were selected for the suitable lyophilization behavior and the acceptable physical
appearance of the resulting products.
The freeze-dried samples appeared soft, porous and friable. Besides the matrix morphology,
the inner structure and surface topography were evaluated by SEM (Figure 2). The images showed
an irregular structure with varying pore sizes and a high porosity that allows a more rapid entrance
of water during dissolution that might mean an increased drug release rate. No drug crystal or
aggregation of particles was visible in the photograph.
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The results showed an average content of MTR and CUR of 9.57% and 0.25% (w/w), respectively.
The tablets have been designed to adhere and swell once applied on the mucosae, promoting
an adequate penetration of both hydrophilic and hydrophobic actives. Indeed, they allow a precise
location and adhesion on the target site, an extended retention time of formulation and an enhanced
delivery in situ of actives.
Buccal tablets were prepared from the compression of aliquots of sponges obtained after the
freeze-drying process. Tablets of 20 mg (A) and 200 mg (B) of sponge were made to perform different
characterization experiments.
The reproducibility of the tablet’s preparation has been assessed measuring the average weight
and thickness of both A and B ones. They were respectively 20 ± 0.3 mg, 2.34 ± 0.05 mm for Tablet A
and 200 ± 1.2 mg 3.31 ± 0.05mm for Tablet B. All data are following the requirements of the Italian
Pharmacopoeia (F.U. XII ed.) and confirm high product reproducibility.
After compression, they preserved the porous structure generated during the freeze-drying
process, with the solvent removal. When the structure surrounding the liquid is rigid enough to
prevent pore collapse, the pore structure is retained. So, the remaining space originally occupied by the
solvent becomes pores in the scaffold. By investigation, the porosity of the tablets was calculated to be
96, 8%. This value was perfectly in accordance with the spongy matrix shown in the images obtained
by SEM analyses.
For a suitable behavior and a sustained and controlled drug release, water penetration and tablet
hydration capacity are critical properties here evaluated performing swelling tests as weight and
optic assessments. Weight variations of the tablets are expressed as perceptual weight increase versus
time, and they are reported in Figure 3. The data showed a rapid increase in weight in the first
20 min-interval, equal to 60% of the initial one, due to the absorption of saliva and the consequent
swelling. After this time a much slower fluid absorption follows due to the formation of a viscous gel
layer (Figure 4) that remains on the mucosa until a slow erosion phenomenon occurs.
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Figure 4. Tablet after 60 min of con act with simulated saliva.
The plan and frontal optical assessments (Figure 5) were carried out to easure the surface area of
the oral mucosa, which is effectively covered by the tablet when dissolution occurs once it was applied
on the target site. Both the frontal and plan photographs showed that the swelling of the tablet in the
first 20 min was due to the main absorption of saliva that does not involve a large increase in volume
and a partial loss of weight, and dissolution occur in 120 min.
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3.3. Ex Vivo Mucoadhesion Strength Measurement
The mucoadhesive prop rties of b ccal tablets influence the ability of the dosage form to be
retained at the site of action, in intimate contact with the target site. For designing mucoadhesive
tablets, polymers as polyacrylic acid and cellulose derivatives are often chosen for their suitable
physical and chemical properties. Ex vivo mucoadhesion strength measurements were performed in
triplicate by a modified two-armed physical balance, applying the tablets on fresh-cut porcine buccal
mucosa. Variation in adhesive strength as a function of contact time was evaluated, and as is shown
in Table 3, the mucoadhesive force increased with the increase of the contact time of formulation
with mucin.
These suitable mucoadhesive properties are enhanced by the use of Natrosol and PVP-K90,
polymers able to form addition bonds with mucins increasing the residence time of formulation on
target mucosal site.
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Table 3. Force of adhesion and detachment force of the tablet after different contact time on the porcine
buccal mucosa (n = 3).
Contact Time (min) Force of Adhesion (N) Detachment Force (N/m2)
5 0.064 486.81
10 0.073 549.50
15 0.100 752.35
20 0.146 1095.33
The release of drug molecules or nanoparticles from prepared tablets is necessary for their
transport into and across the buccal membrane to exhibit therapeutic activity. However, the release of
drugs from a swellable matrix depends on water diffusion into the matrix, polymer swelling and gel
formation, then drug diffusion through the gel or its liberation from the gel [43].
Figure 6 analyses the dose fraction of CUR and MTR released from Tablet A at specific time points.
The period of the drug release testing was kept for 3 h, as about 60% of MTR and 17% of CUR release
were observed during this time.Polymers 2019, 11, x FOR PEER REVIEW 14 of 18 
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Different physico-chemical phenomena are involved in the matrix tablet release mechanism.
From the data, it is possible to highlight that there is a lag time in the release of CUR, probably because
the matrix must initially absorb water and subsequently swell, then releasing the NLC containing CUR.
This phenomenon is much less evident in the release profile of the MTR as it dissolves immediately in
the fluid absorbed by the tablet and diffuses through it. By the fitting the mathematical models that are
useful for comprehension of all the phenomena affecting drug release kinetics, the modified form of
Korsmeyer–Peppas model, as described:
Mt
M∞
= K(t− l)n
where Mt is the amount of drug released over time t, M∞ is the amount of drug contained in the dosage
form at the beginning of the release process, K is the constant of incorporation of characteristics of the
Polymers 2019, 11, 1801 15 of 19
system, n is the exponent of release (related to the drug release mechanism and geometry of dosage
form) in function of time t and l is the latency time, which marks the beginning of drug release from
the system; the most appropriate to describe the behavior of our matrix tablet (Figure 6).
Experimental n values obtained by fitting can explain the complex phenomena that occur during
MTR and CUR-NLC release from the tablet. Possibly, the MTR behavior follows a Fickian model (n
= 0.45, for cylinders) and the release is governed primarily by diffusion. MTR is readily solubilized,
and the solvent transport rate or diffusion is much greater than the process of polymeric chains
relaxation. For CUR-NLC release, the value n = 0.77 indicates that the model is non-Fickian or
anomalous transport, and the mechanism of drug release is governed by both diffusion and swelling.
This could be attributed to the hydrophobicity or dimensions of the nanoparticles, so that their diffusion
through the matrix is influenced by the swelling or relaxation of polymeric chains.
3.4. Ex Vivo Permeation and Penetration of CUR and MTR throughout Porcine Mucosa
The ability of the tablets to release CUR and MTR and the aptitude of actives to penetrate and/or
permeate the membrane was evaluated using vertical Franz type diffusion cells and porcine buccal
mucosa, a useful model to simulate human epithelium [34].
The spectrophotometric analyses demonstrate that just MTR permeates the buccal membrane,
indicating its increasing concentration in the acceptor compartment. The drug movements from tablets
to artificial plasma expressed as an accumulative amount of permeated MTR versus time, are showed
in Figure 7.
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Figure 7. Plot of the cumulative amount of MTR permeated across porcine buccal mucosa vs. time
from Tablet A soaked with simulated saliva. Values are presented as means ± SE (n = 12).
Tablets applied on porcine buccal mucosa for four hours produced massive input of MTR in
the acceptor compartment and the extrapolated flux (Js) per unit area of MTR through the mucosal
membrane at the steady state resulted 0.0731 mg/cm2 h (Figure 8). However, the experiments of drug
permeation occurred from just one side of the tablet adhered on the mucosa, while in vivo conditions
may imply that each side of tablets is in contact with the mucosa. So, a tablet of 1 cm2 produces a drug
flux of about 0.146 mg/cm2h.
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Figure 8. Linear fit at the steady state of MTR permeation per cm2 of porcine sublingual mucosa.
The residual CUR and MTR entrapped into the membrane were quantified by methanol extraction
and analyzed respectively by HPLC and UV-Vis assays. After 4 h, the average amounts extracted
were 0.0032 mg of CUR and e 0.0835 mg of MTR, that are respectively 6.31% and the 4.37% of the dose
applied. These results demonstrate the ability of NLC to promote the penetration of CUR through the
lipophilic domains of the mucosal membrane, where its accumulation can carry out its antioxidant
activity. Moreover, results show that MTR is also able to penetrate and permeate the mucosal tissue,
where it can perform a loco-regional antibacterial activity. The Ac parameter calculated for both
the actives, 0.1006 and 0.0687 cm for CUR and MTR, respectively, demonstrated that the lipophilic
molecule CUR possesses great tendency to penetrate lipophilic domains of membrane and accumulate
into that. On the other hands, CUR is very scarcely soluble in aqueous fluids so that, without lipid
nanocarriers, it cannot penetrate the tissue. By contrast, the MTR having a fair solubility in aqueous
fluids, and due to its partition coefficient, can diffuse through the tissues and be distributed both in
aqueous and lipophilic domains.
4. Conclusions
In this work, a novel buccal drug delivery system for the topical treatment of oral diseases related to
both oxidative stress and bacterial overgrowth was designed. Nanostructured lipid carriers containing CUR
have been formulated, characterized and successfully incorporated into a mucoadhesive hydrophilic sponge
also containing MTR. The buccal tablets obtained by soft compression of sponge showed an appropriate
porosity and swelling index as well as mucoadhesion strength. Ex vivo studies have shown that the tablets
are able to release the actives promoting CUR penetration and MTR permeation. The obtained results
encourage further studies about the possibility to use these matrix systems to deliver in situ antioxidant
and antimicrobial agents to treat several diseases that affect oral mucosae. Finally, this matrix tablet was
specifically designed to contrast oral infections, for which MTR is the drug of choice. However, this new
DDS could be loaded with other drugs and potentially be useful for various pathologies affecting other
mucous membranes (e.g., vaginal, rectal or nasal).
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